Daniel Serrano is currently making significant strides as the Co-Principal Investigator for the U01FD006687-01 project at Uncle Sam, where he is at the forefront of developing a qualified Patient-Reported Outcome (PRO) measure for individuals suffering from Bronchiectasis. With a robust academic foundation from the University...
Daniel Serrano is currently making significant strides as the Co-Principal Investigator for the U01FD006687-01 project at Uncle Sam, where he is at the forefront of developing a qualified Patient-Reported Outcome (PRO) measure for individuals suffering from Bronchiectasis. With a robust academic foundation from the University of North Carolina at Chapel Hill, Daniel has cultivated a unique blend of expertise in psychometrics and epidemiology, which he adeptly applies to clinical trial design and endpoint development. His early career experiences working alongside renowned figures such as Richard Lipton, Buzz Stewart, and Marcelo Bigal on large-scale neurological population surveys have equipped him with invaluable insights into patient-centered research methodologies.
In his current role, Daniel is leading the psychometric validation study phase, a critical component that ensures the reliability and validity of the PRO measure. His work not only emphasizes the importance of capturing patient experiences but also aligns with regulatory strategies that facilitate the acceptance of these measures in clinical settings. Daniel's skills in biostatistics and study design are instrumental in building and maintaining effective teams, fostering collaboration among multidisciplinary experts to drive the project forward. As he navigates the complexities of regulatory affairs, his commitment to enhancing the quality of life for patients with Bronchiectasis remains unwavering. This journey, marked by a passion for impactful research and a dedication to patient advocacy, continues to be a magical ride for Daniel Serrano, who is poised to make lasting contributions to the field of clinical research.
